Related Experiment Video
Updated: Feb 5, 2026

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
Published on: May 24, 2024
Radioembolization with yttrium-90 glass microspheres for patients with hepatocellular carcinoma: a review
1Klinikum Niederrhein, Department of Medicine I, Duisburg & University Hospital of Essen, Essen, Germany.
Abstract:
Clinical studies have evaluated the safety and efficacy of radioembolization with yttrium-90 in patients with unresectable hepatocellular carcinoma (HCC). Citing literature published within the last 5 years, we review the clinical evidence of survival outcomes and safety of yttrium-90 treatment in patients with unresectable HCC. This paper is primarily focused on survival rates following the typical application of yttrium-90 in HCC treatment, and also includes time to progression and safety data. Also discussed are special indications and new developments related to yttrium-90 therapy in HCC, as well as patient selection and its correlation with successful treatment outcomes.
Related Concept Videos
The Looking Glass Self
Review and Preview
Percentiles are a type of fractile that partition data into...
Review and Preview
Patient-centered Care
Drug Dosing: Geriatric Patients
Drug Dosing: Obese Patients

